Blood cancer occurs primarily due to the irregular growth of cells, which includes a variety of malignancies, including leukaemia, lymphoma, and myeloma. Tumours within the bone marrow or lymphatic tissues are often the outcome of aberrant cell development in blood cancer. These tumours can disrupt the generation of normal blood cells, resulting in infections and decreased clotting. During advanced stages, blood cancer cells could leak into the peripheral bloodstream, causing circulation throughout the body. This dispersion can cause metastases to other organs, adding to the systemic aspect of blood cancer. Leukaemia is a blood cancer that develops in the bone marrow, where blood cells are generated. It is characterised by the fast creation of aberrant white blood cells, which interfere with the normal generation of red blood cells and platelets. It can be acute or chronic, depending on the speed of advancement and the type of white blood cells that are affected. According to The Leukaemia & Lymphoma Society, a charitable organisation based in the United States, one person is diagnosed with leukaemia, lymphoma, or myeloma every three minutes, and new cases of leukaemia, lymphoma, and myeloma are expected to account for 9.4% of the total new cancer cases diagnosed in the United States in 2023. CAR T-cell therapy revolutionises cancer treatment by meticulously directing the immune system to attack cancer cells. This groundbreaking approach involves crafting chimeric antigen receptors (CARs) designed to identify and bind to specific antigens on the surface of leukaemia cells. In the case of B-cell leukaemia, the precision is heightened by targeting unique antigens like CD19, elevating the treatment's effectiveness. The growing demand for specialised institutes dedicated to blood cancer treatment plays a pivotal role in propelling the advancement of CAR T-cell therapy. These institutes actively drive research forward, conduct rigorous clinical trials, deliver specialised patient care, and contribute significantly to the overall progress of CAR T-cell therapy. In January 2024, Fortis Healthcare announced the launch of the Fortis Institute of Blood Disorders, a cutting-edge facility dedicated to the specialised treatment of blood cancers and diseases. It is designed to address a wide range of blood problems, combines paediatric and geriatric treatment, advanced transplant procedures, and hematopathology expertise. The institute offers innovative CAR-T cell therapy and NexCAR19 for its extensive network of Bone Marrow Transplant centres in Mohali, Delhi, Gurgaon, Noida, Mumbai, and Bengaluru. This initiative has been supported by a business collaboration with ImmunoACT, an IIT-Bombay spin-off that created India's first entirely indigenous and commercially authorised gene-modified cell therapy. NexCAR19, India's first market-approved CAR-T cell therapy, provides a new ray of hope for treating B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 and above. As a result, the growing prevalence of blood cancer supports the growth of institutes specialising in the treatment of blood cancer. These institutes actively participate in clinical trials focused on evaluating the safety and efficiency of CAR T-cell therapies, which is further anticipated to drive the Global CAR T-cell therapy Market during the forecast period 2023-2030.
According to a market report published by Bizwit Research & Consulting, LLP, the Global CAR T-Cell therapy market is valued at approximately USD 2036.36 million in 2022 and is anticipated to grow with a CAGR of around 39.40% during the forecast period 2023-2030.
The global market for CAR T-Cell therapy is anticipated to grow over the forecast period, owing to rising emphasis on research and development based on advanced cell therapies and supportive government initiatives towards cancer treatment therapies. However, the risk of potential side effects related to CAR T-Cell Therapies and the high treatment cost associated with CAR T-Cell Therapies are hindering the market growth over the forecast period 2023-2030.
Research and development efforts in advanced cell treatments result in novel therapeutic techniques and technology. This innovation is critical for meeting unmet medical needs and increasing the efficacy of existing medicines. Research efforts are aimed at reducing the negative effects of modern cell therapies. Improving the safety profile of these medicines is critical for wider adoption and acceptance in the medical field. Advanced cell therapies, such as CAR T-cell therapy, are frequently tailored to specific individuals. Research contributes to the development of personalised treatment strategies based on a patient's specific genetic and molecular profile, resulting in more precise and focused medicines. For instance, in January 2024, AbbVie and Umoja Biopharma, an early clinical-stage biotechnology company, announced two exclusive option and license agreements to develop various in-situ produced CAR-T cell treatment candidates in oncology on Umoja's patented VivoVecTM platform. The first deal gives AbbVie the exclusive right to licence Umoja's CD19-directed in-situ produced CAR-T cell therapy prospects. This includes Umoja's flagship clinical programme for hematologic malignancies, UB-VV111, which is now in the IND-enabling phase. Under the terms of the second agreement, AbbVie and Umoja are going to collaborate to develop up to four additional in-situ produced CAR-T cell therapy candidates for AbbVie-selected discovery targets. Hence, rising emphasis on research and development based on advanced cell therapies is anticipated to create lucrative growth prospects for the market during the forecast period 2023-2030.
Global CAR T-Cell Therapy Market is segmented into Indication, Drug Type and by End Use. The Total Market revenue is calculated based on the revenue generated from the commercialisation of Chimeric Antigen Receptor (CAR) T-cell therapies. The major key players in the market are Caribou Biosciences Inc., Autolus Therapeutics, Cartesian Therapeutics Inc., Bluebird bio, Inc., Merck & Co. Inc., Bristol-Myers Squibb, Novartis AG, PeproMene Bio. Inc., Amgen Inc. and Gilead Sciences Inc. (Kite Pharma Inc.). Other popular regional players across various countries are also considered for revenue calculation.
